Exelixis Stock Price, News & Analysis (NASDAQ:EXEL)

$28.00 0.14 (0.50 %)
(As of 01/22/2018 09:27 AM ET)
Previous Close$27.86
Today's Range$27.68 - $28.32
52-Week Range$16.72 - $32.50
Volume4.68 million shs
Average Volume3.26 million shs
Market Capitalization$8.28 billion
P/E Ratio57.14
Dividend YieldN/A
Beta1.88

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.32%
Quick Ratio4.27%

Price-To-Earnings

Trailing P/E Ratio57.1428571428571
Forward P/E Ratio57.14
P/E Growth0.84

Sales & Book Value

Annual Sales$191.45 million
Price / Sales43.27
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book90.32

Profitability

Trailing EPS$0.49
Net Income$-70,220,000.00
Net Margins36.80%
Return on Equity105.47%
Return on Assets27.22%

Miscellaneous

Employees287
Outstanding Shares295,850,000

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.08 by $0.18. The biotechnology company earned $152.50 million during the quarter, compared to analyst estimates of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business's revenue was up 145.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.04) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2018?

12 brokerages have issued twelve-month target prices for Exelixis' shares. Their forecasts range from $26.00 to $39.00. On average, they anticipate Exelixis' share price to reach $31.71 in the next twelve months. View Analyst Ratings for Exelixis.

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. Cann analysts commented, "Exelixis announced today an amendment to the protocol for the phase Ib trial of Cabometyx (cabozantinib) in combination with atezolizumab (Tecentriq) in patients with locally advanced or metastatic solid tumors. Exelixis reported the amendment adds four new expansion cohorts to the trial, which will now include patients with non- small cell lung cancer (NSCLC) and castration-resistant prostate cancer (CRPC), in addition to previously included patients with renal cell carcinoma (RCC) and urothelial carcinoma (UC). The primary objective in the expansion stage of this trial remains to determine the objective response rate in each cohort. Exelixis confirmed the original trial protocol included four expansion cohorts, which will remain in the amended study unchanged." (1/4/2018)
  • 2. According to Zacks Investment Research, "Exelixis' lead drug Cabometyx posted strong sales in the first nine months of 2017 thereby underlying the increasing demand for the drug. New patient market share in the second line plus setting increased to 38%. The recent FDA approval of Cabometyx for the treatment previously untreated advanced RCC should further boost demand. The drug performed impressively against widely used Sutent. We expect Cabometyx will pose a challenge to Sutent’s market share for first line RCC in 2018. The approval comes two months ahead of schedule. The drug is also being evaluated for advanced hepatocellular carcinoma (HCC) in the CELESTIAL study. Exelixis also has collaborations with Bristol-Myers and Roche on the development of the drug in combination with immunotherapy agents. Moreover, Exelixis’ share price has outperformed the industry in 2017. However, the company is heavily dependent on Cabometyx for growth." (1/2/2018)

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder (Age 68)
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director (Age 56)
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President (Age 49)
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer (Age 60)
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer (Age 56)
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary (Age 48)
  • Patrick Haley, Senior Vice President - Commercial (Age 41)
  • Charles M. Cohen Ph.D., Independent Director (Age 66)
  • Carl B. Feldbaum Esq., Independent Director (Age 73)
  • Alan M. Garber M.D. Ph.D., Independent Director (Age 61)

Who owns Exelixis stock?

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Meditor Group Ltd (5.57%), Bank of Montreal Can (0.39%), Schwab Charles Investment Management Inc. (0.35%), Acadian Asset Management LLC (0.10%), Creative Planning (0.04%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Meditor Group Ltd. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, State of Alaska Department of Revenue, Creative Planning and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $28.00.

How big of a company is Exelixis?

Exelixis has a market capitalization of $8.28 billion and generates $191.45 million in revenue each year. The biotechnology company earns $-70,220,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. Exelixis employs 287 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (EXEL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Exelixis (NASDAQ:EXEL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.64
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.71$31.71$31.29$19.80
Price Target Upside: 16.81% upside14.04% upside7.81% upside26.00% downside

Exelixis (NASDAQ:EXEL) Consensus Price Target History

Price Target History for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018OppenheimerReiterated RatingHoldHighView Rating Details
1/4/2018CannReiterated RatingHoldMediumView Rating Details
12/21/2017SunTrust BanksReiterated RatingBuy$38.00HighView Rating Details
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $33.00N/AView Rating Details
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$33.00 -> $39.00N/AView Rating Details
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
9/22/2017Leerink SwannDowngradeOutperform -> Market Perform$34.00 -> $28.00HighView Rating Details
8/10/2017CowenReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche BankDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
7/27/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Exelixis (NASDAQ:EXEL) Earnings History and Estimates Chart

Earnings by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.12N/AView Earnings Details
11/1/2017Q3 2017$0.08$0.26$104.91 million$152.50 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)$0.37ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.17)($0.12)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.31)($0.25)ViewN/AView Earnings Details
3/9/2010Q4 2009($0.27)($0.25)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.33)($0.22)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.41)($0.33)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.31)($0.36)ViewN/AView Earnings Details
3/4/2009Q4 2008($0.35)($0.36)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.41)($0.39)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.39)($0.43)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.37)($0.39)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.28)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Exelixis (NASDAQ:EXEL) Earnings Estimates

2018 EPS Consensus Estimate: $0.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.09$0.13$0.11
Q2 20183$0.11$0.15$0.14
Q3 20183$0.16$0.17$0.16
Q4 20183$0.21$0.36$0.26
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 80.92%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2018Alan M GarberDirectorSell15,000$30.30$454,500.0064,829View SEC Filing  
9/28/2017Gisela SchwabInsiderSell100,000$23.79$2,379,000.00View SEC Filing  
9/28/2017Jeffrey HessekielEVPSell27,302$24.28$662,892.56View SEC Filing  
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00518,273View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.0452,721View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00130,070View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.5078,110View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.001,238,471View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00238,180View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00160,070View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.5086,405View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00174,354View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00548,273View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00548,273View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00494,975View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.2036,473View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.0036,473View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.8436,473View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00333,700View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Exelixis (NASDAQ EXEL) News Headlines

Source:
DateHeadline
Exelixis (EXEL) Announced Updated Phase 1b Results for Combination of Cobimetinib and Atezolizumab in Metastatic ... - StreetInsider.comExelixis (EXEL) Announced Updated Phase 1b Results for Combination of Cobimetinib and Atezolizumab in Metastatic ... - StreetInsider.com
www.streetinsider.com - January 22 at 5:55 AM
Exelixis (EXEL) Rating Lowered to Hold at BidaskClubExelixis (EXEL) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - January 21 at 3:34 PM
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab ... - Business Wire (press release)Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab ... - Business Wire (press release)
www.businesswire.com - January 20 at 3:17 PM
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumExelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
finance.yahoo.com - January 20 at 11:05 AM
Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib ... - Business Wire (press release)Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib ... - Business Wire (press release)
www.businesswire.com - January 18 at 10:27 AM
Oppenheimer Reaffirms Hold Rating for Exelixis (EXEL)Oppenheimer Reaffirms Hold Rating for Exelixis (EXEL)
www.americanbankingnews.com - January 17 at 1:34 PM
Exelixis, Ipsen Report Positive Results on Lead Cancer DrugExelixis, Ipsen Report Positive Results on Lead Cancer Drug
finance.yahoo.com - January 17 at 9:26 AM
Exelixis, Ipsen report cancer drug success in late-stage studyExelixis, Ipsen report cancer drug success in late-stage study
seekingalpha.com - January 16 at 8:39 PM
Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular CarcinomaExelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma
finance.yahoo.com - January 16 at 5:13 PM
Why Vertex Pharmaceuticals Raised Its 2017 Revenue GuidanceWhy Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
finance.yahoo.com - January 16 at 9:40 AM
Novartis (NVS) Announces Acceptance of Humira BLA by the FDANovartis (NVS) Announces Acceptance of Humira BLA by the FDA
finance.yahoo.com - January 16 at 9:40 AM
Analyst Recommendations for Vertex Pharmaceuticals in JanuaryAnalyst Recommendations for Vertex Pharmaceuticals in January
finance.yahoo.com - January 16 at 9:40 AM
Research Analysts Offer Predictions for Exelixis, Inc.s FY2022 Earnings (EXEL)Research Analysts Offer Predictions for Exelixis, Inc.'s FY2022 Earnings (EXEL)
www.americanbankingnews.com - January 15 at 5:14 PM
Glaxo's Influenza Vaccine Gets FDA Nod for Label ExpansionGlaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
finance.yahoo.com - January 15 at 9:31 AM
Exelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $118.16 MillionExelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $118.16 Million
www.americanbankingnews.com - January 14 at 9:56 AM
Form 4 EXELIXIS, INC. For: Jan 08 Filed by: Garber Alan MForm 4 EXELIXIS, INC. For: Jan 08 Filed by: Garber Alan M
www.streetinsider.com - January 11 at 5:21 PM
4 Reasons Exelixis, Inc. More Than Doubled in 2017 - Motley Fool4 Reasons Exelixis, Inc. More Than Doubled in 2017 - Motley Fool
www.fool.com - January 11 at 9:54 AM
Exelixis - Looking Good For 2018 - Seeking AlphaExelixis - Looking Good For 2018 - Seeking Alpha
seekingalpha.com - January 11 at 9:54 AM
Alan M. Garber Sells 15,000 Shares of Exelixis, Inc. (EXEL) StockAlan M. Garber Sells 15,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - January 10 at 9:38 PM
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock UpAdamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up
finance.yahoo.com - January 10 at 9:41 AM
Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical ... - Business Wire (press release)Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical ... - Business Wire (press release)
www.businesswire.com - January 9 at 5:18 PM
Acorda's Shares Down on Disappointing Ampyra View for 2018Acorda's Shares Down on Disappointing Ampyra View for 2018
finance.yahoo.com - January 9 at 5:18 PM
Exelixis (EXEL) And StemSynergy Enter into Pact for Discovery and Development of Novel Anticancer TherapiesExelixis (EXEL) And StemSynergy Enter into Pact for Discovery and Development of Novel Anticancer Therapies
www.streetinsider.com - January 9 at 9:36 AM
Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%
finance.yahoo.com - January 9 at 9:36 AM
Exelixis, Inc. (EXEL) to Post FY2017 Earnings of $0.45 Per Share, Leerink Swann ForecastsExelixis, Inc. (EXEL) to Post FY2017 Earnings of $0.45 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 8 at 2:28 AM
Exelixis (EXEL) Raised to Buy at BidaskClubExelixis (EXEL) Raised to Buy at BidaskClub
www.americanbankingnews.com - January 6 at 11:08 AM
4 Biotech Stocks to Watch in the New Year4 Biotech Stocks to Watch in the New Year
finance.yahoo.com - January 5 at 5:00 PM
Exelixis (EXEL) Amends Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in ... - StreetInsider.comExelixis (EXEL) Amends Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in ... - StreetInsider.com
www.streetinsider.com - January 4 at 5:16 PM
The Secret Sauce Behind Exelixis, Inc.s 12% Move Higher in December - Motley FoolThe Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December - Motley Fool
www.fool.com - January 4 at 5:16 PM
Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic ...Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic ...
www.businesswire.com - January 4 at 5:16 PM
Exelixis (EXEL) Stock Rating Reaffirmed by OppenheimerExelixis (EXEL) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - January 4 at 12:40 PM
Exelixis (EXEL) Hold Rating Reiterated at CannExelixis' (EXEL) Hold Rating Reiterated at Cann
www.americanbankingnews.com - January 4 at 11:18 AM
Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%
www.zacks.com - January 4 at 9:35 AM
BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With AtezolizumabBRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab
www.reuters.com - January 4 at 9:35 AM
Inovio Amends Chinese Deal for Immunotherapy, Shares UpInovio Amends Chinese Deal for Immunotherapy, Shares Up
www.zacks.com - January 3 at 8:46 AM
Exelixis (EXEL) Lifted to Strong-Buy at Zacks Investment ResearchExelixis (EXEL) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM
Exelixis, Inc. (EXEL) Given Average Recommendation of "Buy" by BrokeragesExelixis, Inc. (EXEL) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 29 at 8:30 AM
Will Exelixis (EXEL) be Able to Carry 17 Momentum in 2018?Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
www.nasdaq.com - December 28 at 10:52 AM
Stocks Showing Market Leadership: Exelixis Earns 93 RS RatingStocks Showing Market Leadership: Exelixis Earns 93 RS Rating
finance.yahoo.com - December 28 at 10:52 AM
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
finance.yahoo.com - December 28 at 10:52 AM
ETFs with exposure to Exelixis, Inc. : December 26, 2017ETFs with exposure to Exelixis, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 10:52 AM
Exelixis Target of Unusually High Options Trading (EXEL)Exelixis Target of Unusually High Options Trading (EXEL)
www.americanbankingnews.com - December 28 at 4:05 AM
 Analysts Expect Exelixis, Inc. (EXEL) to Announce $0.12 EPS Analysts Expect Exelixis, Inc. (EXEL) to Announce $0.12 EPS
www.americanbankingnews.com - December 26 at 7:21 PM
Research Analysts Set Expectations for Exelixis, Inc.s FY2019 Earnings (EXEL)Research Analysts Set Expectations for Exelixis, Inc.'s FY2019 Earnings (EXEL)
www.americanbankingnews.com - December 22 at 7:31 PM
Exelixis (EXEL) "Buy" Rating Reaffirmed at SunTrust BanksExelixis' (EXEL) "Buy" Rating Reaffirmed at SunTrust Banks
www.americanbankingnews.com - December 21 at 8:40 PM
FY2018 Earnings Estimate for Exelixis, Inc. (EXEL) Issued By SunTrust BanksFY2018 Earnings Estimate for Exelixis, Inc. (EXEL) Issued By SunTrust Banks
www.americanbankingnews.com - December 21 at 6:56 PM
Whats Happening in Advanced Renal Cell Carcinoma Space?What's Happening in Advanced Renal Cell Carcinoma Space?
www.zacks.com - December 21 at 9:36 AM
What's Happening in Advanced Renal Cell Carcinoma Space?What's Happening in Advanced Renal Cell Carcinoma Space?
finance.yahoo.com - December 21 at 9:36 AM
Exelixis Cabometyx Gets FDA Nod for First-Line Kidney CancerExelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
finance.yahoo.com - December 20 at 5:13 PM
Stocks Showing Improving Market Leadership: Exelixis Earns 83 RS RatingStocks Showing Improving Market Leadership: Exelixis Earns 83 RS Rating
finance.yahoo.com - December 20 at 5:13 PM

SEC Filings

Exelixis (NASDAQ:EXEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Exelixis (NASDAQ EXEL) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.